Skip to main navigation

Skip to Content

Overview
Stock Information
SEC Filings
Corporate Governance
Company
Contact Us
ImmunityBio.com

Press Releases

Press Releases

Year

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival

Jan 18, 2022

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness

Jan 12, 2022

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

Jan 04, 2022

Amyris and Immunitybio Complete Joint Venture for Next Generation Covid-19 RNA Vaccine

Jan 03, 2022

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 14 of 14

IR Tools

© 2022 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘Conkwest’, ‘haNK’, ‘taNK’, ‘vaNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Neukosome’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Infacell’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, Inc.

Anktiva is a trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

NantKwest

Visit ImmunityBio.com

Social icons